Nature Biotechnology 2017-07-12

CRISPR–Cas9 claim sets and the potential to stifle innovation

Benjamin N Gray, W Murray Spruill

Index: 10.1038/nbt.3913

Full Text: HTML

Extremely broad claims surrounding Cas9 nucleases have the potential to stifle innovation in the field of genome editing.

Latest Articles:

A wellness study of 108 individuals using personal, dense, dynamic data clouds

2017-07-17

[10.1038/nbt.3870]

Nanoscale imaging of clinical specimens using pathology-optimized expansion microscopy

2017-07-17

[10.1038/nbt.3892]

Wanted: biotech for an aging population

2017-07-12

[10.1038/nbt.3925]

An emerging model for life sciences commercialization

2017-07-12

[10.1038/nbt.3911]

Public biotech in 2016—the numbers

2017-07-12

[10.1038/nbt.3917]